Author

ML Johnson

Observed name: M. Johnson

Institution: Sarah Cannon

Observed institutions: Mayo Clinic, Sarah Cannon Research Institute, Sarah Cannon

OpenAlex ID: A5069880396

P1.04-008 POSEIDON: A Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Chemotherapy vs Chemotherapy Alone in Metastatic NSCLC

2017 · T. Mok, M. Johnson, et al. · Journal of Thoracic Oncology · 15

Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study

2017 · W Eberhardt, MC Garassino, et al. · Pneumologie · 1

Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)

2023 · S. Champiat, H. Izumi, et al. · Revue des Maladies Respiratoires Actualités

OC-020 Comparative Effectiveness Of Novel Techniques For Barrett’s Oesophagus (bo) Screening In The Community: A Prospective Randomised Trial

2014 · SS Sami, KT Dunagan, et al. · Gut

Pms23 an Economic Analysis Comparing Three Combinations of Tumor Necrosis Factor-alpha Agents for the Treatment of Rheumatoid Arthritis

2009 · SJ Agarwal, SS Sansgiry, et al. · Value in Health

Works count: 5

Citation count: 16

H-index: 1

I10-index: 1